Characterization of monoclonal antibodies developed against Sarcocystis neurona

Equine protozoal myeloencephalitis (EPM), caused by a protozoal parasite infection of the central nervous system, is the most commonly diagnosed neurologic disease of horses in North America. In specific regions of the United States approximately 50% of the horse population is seropositive to Sarcocystis neurona. However, not all seropositive horses develop clinical signs. Detailed clinical examination, along with cerebrospinal fluid antibody evaluation are often used to diagnose EPM. Postmortem evaluation of the brain stem and spinal cord for histopathologic lesions compatible with nonsuppurative meningoencephalomyelitis is used for reaching a diagnosis since organisms are difficult to detect by routine staining methods. Immunohistochemical staining aids detection of organisms; however, the polyclonal antibodies that react with S. neurona may react with merozoites of other closely related Sarcocystis species. In this study, two different monoclonal antibodies, mAb 2A7-18 and mAb 2G5-2, were developed against the merozoite stage of S. neurona UCD-SN1 strain. The antibodies were evaluated by immunoblot, immunofluorescence, immuno-electron microscopy and immunohistochemistry for their ability to react with S. neurona. MAb 2G5-2 reacted with antigenically distinct S. neurona isolates whereas mAb 2A7-18 appeared to be limited in its ability to recognize different isolates. These two monoclonal antibodies recognize protein epitopes of two different immunodominant proteins of S. neurona.